Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Agonist antibodies

a technology of agonist antibodies and rtpo153, which is applied in the field of recombinant synthesis and purification of protein antibodies, can solve the problems of ineffective single doses of unglycosylated rtpo153, the inability to destroy essential stromal cells or components, and the inability to kill the body with radiation, etc., to achieve the effect of improving or modulating the half-li

Inactive Publication Date: 2005-09-22
ADAMS CAMELLIA +3
View PDF2 Cites 11 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0031] In one embodiment, the objects of the invention are achieved by providing an antibody or fragment thereof that activates a hematopoietic growth factor superfamily receptor having a biological activity within 2 orders of magnitude (100), preferably within one order of magnitude (10), of the natural ligand on a weight basis Preferably, the antibody activates the thrombopoietin (TPO) receptor. This antibody, referred to as an agonist antibody, activates a thrombopoietin receptor which preferably comprises a mammalian c-mpl, more preferably human c-mpl. Usually the antibody will be a full length antibody such as an IgG antibody. Suitable representative fragment agonist antibodies include Fv, ScFv, Fab, F(ab′)2 fragments, as well as diabodies and linear antibodies. These fragments may be fused to othersequences including, for example, the F″ or Fc region of an antibody, a “leucine zipper” or other sequences including pegylated sequences or Fc mutants used to improve or modulate half-life. Normally the antibody is a human antibody and may be a non-naturally occurring antibody, including affinity matured antibodies. Representative antibodies that activate c-mpl are selected from the group 12E10, 12B5, 10F6 and 12D5, and affinity matured derivatives thereof. Other preferred agonist antibodies to c-mpl are selected from the group consisting of Ab1, Ab2, Ab3, Ab4, Ab5 and Ab6, wherein each Ab1-Ab6 contains a VH and VL chain and each VH and VL chain contains complementarity determining region (CDR) amino acid sequences designated CDR1, CDR2 and CDR...

Problems solved by technology

The reason for this discrepancy is unclear, however it is possible that lethal radiation may destroy stromal cells or components essential for TPO activity in vivo.
This is supported by the fact that single doses of unglycosylated rTPO153 are not effective in this model.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Agonist antibodies
  • Agonist antibodies
  • Agonist antibodies

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0200] Assays

[0201] The mpl agonist antibody assays were conducted essentially as described in WO 95 / 18858.

[0202] (a) Ba / F3 Cell Proliferation Assay

[0203] The Ba / F3-mpl cell line was established (F. de Sauvage et al., Nature, 369:533 (1994)) by introduction of the cDNA encoding the entire mpl receptor into the IL-3 dependent murine lymphoblastoid cell line Ba / F3. Simulation of proliferation of Ba / F3-mpl cells in response to various concentrations of antibodies or TPO was measured by the amount of incorporation of 3H-thymidine as previously described (F. de Sauvage et al., supra).

[0204] (b) CMK Assay for Induction of Platelet Antigen GPIIbIIIa Expression

[0205] CMK cells are maintained in RMPI 1640 medium (Sigma) supplemented with 10% fetal bovine serum and 10 mM glutamine. In preparation for the assay, the cells are harvested, washed and resuspended at 5×105 cells / ml in serum-free GIF medium supplemented with 5 mg / l bovine insulin, 10 mg / l apo-transferrin, 1× trace elements. In ...

example 2

[0229] Isolation of Antibodies from the CAT Library

[0230] For construction of a library of antibodies displayed of a phage see the following references: WO 92 / 01047, WO 92 / 20791, WO 93 / 06213, WO 93 / 11236, WO 93 / 19172, WO 95 / 01438 and WO 95 / 15388. Briefly, FIGS. 2 and 3 presents a cartoon of the construction of a phage library containing 6×109 different clones containing single-chain Fv (scFv) antibodies fused to gene 3 of a phage. Binding selection against an antigen, in this case c-mpl, can be carried out as shown in FIG. 4 and described in greater detail below.

[0231] (a) The Antigen

[0232] Human c-mpl was cloned as described by F. de Sauvage et al., Nature 369:533 (1994).

[0233] (b) Phage Selection on Immunotubes

[0234] NUNC immunotubes were coated with 2 ml of a solution of 10 microg / ml of gD-c-mpl in PBS at 4° C. overnight. After rinsing with PBS, tubes were blocked with 3% dry milk in PBS (MPBS) for 2 hr at room temperature. For the first round, 10 μl of C.A.T. antibody phage...

example 3

Cloning and Expression of Full Length Human Antibody Derivatives of 12B5, 12D5, and 12E10

[0291] For expression of full length antibodies in mammalian cells, the heavy chain variable domains were subcloned from the Fab constructs into a derivative of expression vector pRK (Suva et al., Science 237:893-896 (1987)) which contains the human IgG1 CH1, CH2, and CH3 domains and a human antibody signal sequence (Carter et al., Proc. Natl. Acad. Sci. USA. 89:4285-4289 (1992)). The light chain was cloned into a separate pRK plasmid. The light and heavy chain expression vectors were cotransfected into adenovirus-transformed human embryonic kidney cell line 293 by a high-efficiency procedure (Gorman et al, DNA Protein Eng. Technol. 2:3-10 (1990)). Harvested conditioned media was shown to contain anti-mpl antibody by ELISA.

[0292] For production of a more stable cell line and high-level antibody production, the light and heavy chains were moved into the SVI.DI expression vector previously descr...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Fractionaaaaaaaaaa
Login to View More

Abstract

Various forms of c-mpl agonist antibodies are shown to influence the replication, differentiation or maturation of blood cells, especially megakaryocytes and megakaryocyte progenitor cells. Accordingly, these compounds may be used for treatment of thrombocytopenia.

Description

[0001] This application is a non-provisional application filed under 37 CFR 1.53(b), claiming priority under 35 USC 119(e) to provisional application No. 60 / 056,736, filed 22 Aug. 1997, the contents of which are incorporated herein by reference.FIELD OF THE INVENTION [0002] This invention relates to the recombinant synthesis and purification of protein antibodies that influence survival, proliferation, differentiation or maturation of hematopoietic cells, especially platelet progenitor cells and to antibodies that influence the growth and differentiation of cells expressing a protein kinase receptor. This invention also relates to the cloning and expression of nucleic acids encoding antibody ligands (thrombopoietin receptor agonist antibodies) capable of binding to and activating a thrombopoietin receptor such as c-mpl, a member of the cytokine receptor superfamily. This invention further relates to the use of these antibodies alone or in combination with other cytokines to treat im...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K16/28
CPCA61K2039/505C07K16/24C07K16/2866C07K16/40C07K2316/95C07K2317/92C07K2317/54C07K2317/55C07K2317/567C07K2317/622C07K2317/21C07K2317/74C07K2317/75
Inventor ADAMS, CAMELLIACARTER, PAULFENDLY, BRIANGURNEY, AUSTIN
Owner ADAMS CAMELLIA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com